HAVANA, Cuba, Mar 30 (ACN) The National Institute of Oncology and Radiobiology (INOR), in Havana, one of the centers participating in the Soberana 02 intervention study, plans to conclude today the application of the first dose of this vaccine candidate to all its staff.
Jose Antonio Soutuyo Perez, principal investigator of the intervention study at the institution said that the workers of the center have shown very good acceptance and only those who have had COVID-19, an acute infection, those who are treated with steroids, antibiotics or have decompensated pathologies, pregnant women, puerperal women and women who are breastfeeding, according to the exclusion criteria of the study, are not participating in the trial.
Regarding the services of the institution, he said that they were transferred to other departments so that they would not interfere with the vaccination and during these days the hospital kept working at 100 %, as it has been doing since March 11.
In a center like this, with the demand for care it has, it is a security and a guarantee to be vaccinated, and also for the family because of the risk involved in the treatment of patients, even though this is not a COVID-19 hospital, the principal investigator pointed out.
For his part, Dr. Guillermo Roblejo Fonseca, first deputy director of INOR, told ACN they are proud to be recognized by the health ministry with this vaccination, thanks to the work developed during these months.
Throughout the pandemic they have maintained their services, consultations, diagnostic means and surgical procedures, he stressed
Cancer is a disease that cannot be postponed, since it is the second cause of death in the Cuban population, and only at INOR, from Monday to Friday, an average of 150 patients are classified and between 25 and 30 of them are registered every day, the expert concluded.
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio